CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
124.78
1.68%
Market Trading Hours* (UTC) Open now
Closes on Monday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Merck & Co Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 126.9
Open* 126.2
1-Year Change* 18.21%
Day's Range* 124.7 - 126.2
52 wk Range 99.14-119.94
Average Volume (10 days) 7.80M
Average Volume (3 months) 172.98M
Market Cap 300.38B
P/E Ratio 65.68
Shares Outstanding 2.53B
Revenue 59.31B
EPS 1.80
Dividend (Yield %) 2.59828
Beta 0.38
Next Earnings Date Feb 1, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 126.90 0.46 0.36% 126.44 127.78 126.26
Feb 29, 2024 126.80 -1.08 -0.84% 127.88 128.73 126.79
Feb 28, 2024 128.15 0.15 0.12% 128.00 129.30 127.64
Feb 27, 2024 128.99 0.88 0.69% 128.11 129.10 127.63
Feb 26, 2024 128.76 0.11 0.09% 128.65 129.57 128.22
Feb 23, 2024 129.36 0.03 0.02% 129.33 130.18 128.78
Feb 22, 2024 129.19 1.71 1.34% 127.48 129.66 127.48
Feb 21, 2024 128.09 1.52 1.20% 126.57 128.10 126.54
Feb 20, 2024 127.31 -0.03 -0.02% 127.34 129.22 127.15
Feb 16, 2024 127.38 1.66 1.32% 125.72 128.03 125.65
Feb 15, 2024 126.41 1.08 0.86% 125.33 127.17 125.32
Feb 14, 2024 125.76 0.31 0.25% 125.45 125.97 124.73
Feb 13, 2024 125.43 0.18 0.14% 125.25 126.78 124.42
Feb 12, 2024 125.29 0.53 0.42% 124.76 125.41 124.31
Feb 9, 2024 125.37 -0.58 -0.46% 125.95 126.59 124.98
Feb 8, 2024 126.56 -0.54 -0.42% 127.10 127.11 125.89
Feb 7, 2024 127.42 0.91 0.72% 126.51 127.99 126.28
Feb 6, 2024 126.81 0.50 0.40% 126.31 127.45 126.00
Feb 5, 2024 126.09 0.04 0.03% 126.05 127.71 125.61
Feb 2, 2024 126.31 -0.20 -0.16% 126.51 127.47 126.04

Merck & Co Inc - USD Events

Time (UTC) Country Event
Tuesday, March 5, 2024

Time (UTC)

18:30

Country

US

Event

Merck & Co Inc at TD Cowen Health Care Conference
Merck & Co Inc at TD Cowen Health Care Conference

Forecast

-

Previous

-
Thursday, April 25, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Merck & Co Inc Earnings Release
Q1 2024 Merck & Co Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

13:00

Country

US

Event

Q1 2024 Merck & Co Inc Earnings Call
Q1 2024 Merck & Co Inc Earnings Call

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

13:00

Country

US

Event

Merck & Co Inc Annual Shareholders Meeting
Merck & Co Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 59283 48704 41518 39121 42294
Revenue 59283 48704 41518 39121 42294
Cost of Revenue, Total 17206 13241 11583 11060 13065
Gross Profit 42077 35463 29935 28061 29229
Total Operating Expense 41338 36166 36545 31821 33995
Selling/General/Admin. Expenses, Total 9948 9615 8908 9421 10067
Research & Development 11818 10281 10102 8555 7854
Unusual Expense (Income) 2366 3029 5952 2785 3009
Operating Income 17945 12538 4973 7300 8299
Interest Income (Expense), Net Non-Operating -2461 873 421 -636 10
Other, Net 960 468 469 507 392
Net Income Before Taxes 16444 13879 5863 7171 8701
Net Income After Taxes 14526 12358 4523 5606 6482
Minority Interest -7 -13 -4 84 27
Net Income Before Extra. Items 14519 12345 4519 5690 6509
Net Income 14519 13049 7067 9843 6220
Income Available to Common Excl. Extra. Items 14519 12345 4519 5690 6509
Income Available to Common Incl. Extra. Items 14519 13049 7067 9843 6220
Diluted Net Income 14519 13049 7067 9843 6220
Diluted Weighted Average Shares 2542 2538 2541 2580 2679
Diluted EPS Excluding Extraordinary Items 5.71164 4.86407 1.77843 2.20543 2.42964
Dividends per Share - Common Stock Primary Issue 2.8 2.64 2.48 2.26 1.99
Diluted Normalized EPS 7.89442 6.81007 4.69927 3.96379 4.13343
Total Extraordinary Items 0 704 2548 4153 -289
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total revenue 15962 15035 14487 13830 14959
Revenue 15962 15035 14487 13830 14959
Cost of Revenue, Total 3679 3992 3897 3843 3880
Gross Profit 12283 11043 10590 9987 11079
Total Operating Expense 10192 20198 10175.5 10392 10947
Selling/General/Admin. Expenses, Total 2462 2625 2478 2667 2494
Research & Development 3297 13320 4276 2962 3511
Unusual Expense (Income) 754 261 -475.5 920 1062
Operating Income 5770 -5163 4311.5 3438 4012
Interest Income (Expense), Net Non-Operating -17 -405 259 -215 -671
Other, Net -133 233 -920.5 290 242
Net Income Before Taxes 5620 -5335 3650 3513 3583
Net Income After Taxes 4750 -5972 2825 3018 3253
Minority Interest -5 -3 -4 -1 -5
Net Income Before Extra. Items 4745 -5975 2821 3017 3248
Total Extraordinary Items 0 0
Net Income 4745 -5975 2821 3017 3248
Income Available to Common Excl. Extra. Items 4745 -5975 2821 3017 3248
Income Available to Common Incl. Extra. Items 4745 -5975 2821 3017 3248
Diluted Net Income 4745 -5975 2821 3017 3248
Diluted Weighted Average Shares 2546 2539 2541 2548 2542
Diluted EPS Excluding Extraordinary Items 1.86371 -2.35329 1.11019 1.18407 1.27773
Dividends per Share - Common Stock Primary Issue 0.73 0.73 0.73 0.73 0.69
Diluted Normalized EPS 2.19324 -2.15898 1.14507 1.94001 2.1663
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 35722 30266 27764 27483 25875
Cash and Short Term Investments 13192 8096 8062 10450 8864
Cash & Equivalents 12694 8096 8062 9676 7965
Short Term Investments 498 0 774 899
Total Receivables, Net 10110 9230 7851 6778 7071
Accounts Receivable - Trade, Net 9450 9230 7851 6778 7071
Total Inventory 5911 5953 6310 5978 5440
Other Current Assets, Total 6509 6987 5541 4277 4500
Total Assets 109160 105694 91588 84397 82637
Property/Plant/Equipment, Total - Net 22768 19279 17986 16126 13291
Property/Plant/Equipment, Total - Gross 40753 37471 36968 33812 29615
Accumulated Depreciation, Total -17985 -18192 -18982 -17686 -16324
Goodwill, Net 21204 21264 20238 19425 18253
Intangibles, Net 20269 22933 14604 14196 11431
Long Term Investments 2445 966 1371 1889 6233
Other Long Term Assets, Total 6752 10986 9625 5278 7554
Total Current Liabilities 24239 23872 27327 22220 22206
Accounts Payable 4264 4609 4594 3738 3318
Accrued Expenses 13608 13859 13053 12453 10073
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 1946 2412 6431 3610 5308
Other Current Liabilities, Total 4421 2992 3249 2419 3507
Total Liabilities 63169 67510 66271 58490 55936
Total Long Term Debt 28745 30690 25360 22736 19806
Long Term Debt 28745 30690 25360 22736 19806
Deferred Income Tax 1795 3441 1015 1470 1702
Minority Interest 67 73 87 94 181
Other Liabilities, Total 8323 9434 12482 11970 12041
Total Equity 45991 38184 25317 25907 26701
Common Stock 1788 1788 1788 1788 1788
Additional Paid-In Capital 44379 44238 39588 39660 38808
Retained Earnings (Accumulated Deficit) 61081 53696 47362 46602 42579
Treasury Stock - Common -56489 -57109 -56787 -55950 -50929
Unrealized Gain (Loss) 0 0 0 18 -78
Other Equity, Total -4768 -4429 -6634 -6211 -5467
Total Liabilities & Shareholders’ Equity 109160 105694 91588 84397 82637
Total Common Shares Outstanding 2537.83 2527.6 2530.23 2539.02 2592.56
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 31954 29977 33402 35722 33561
Cash and Short Term Investments 8773 6378 10387 13192 11248
Cash & Equivalents 8605 5660 9707 12694 11145
Total Receivables, Net 11485 11748 11104 10110 10118
Accounts Receivable - Trade, Net 10394 11030 10415 9450 9482
Total Inventory 6131 5930 5863 5911 5614
Other Current Assets, Total 5565 5921 6048 6509 6581
Total Assets 106727 104469 107796 109160 107081
Property/Plant/Equipment, Total - Net 22526 22231 21758 21422 20424
Property/Plant/Equipment, Total - Gross 40972 40663 40014 39407 38345
Accumulated Depreciation, Total -18446 -18432 -18256 -17985 -17921
Goodwill, Net 21183 21195 21209 21204 21160
Intangibles, Net 19199 19665 19857 20269 21368
Long Term Investments 2636 2785 2957 2445 2344
Other Long Term Assets, Total 9229 8616 8613 8098 8224
Total Current Liabilities 23094 23394 23131 24239 22998
Accounts Payable 3509 3442 3680 4264 3371
Accrued Expenses 14134 13375 12595 13608 13941
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 887 2839 2672 1946 1936
Other Current Liabilities, Total 4564 3738 4184 4421 3750
Total Liabilities 65481 65776 60962 63169 62623
Total Long Term Debt 33972 34072 28074 28745 28482
Long Term Debt 33972 34072 28074 28745 28482
Deferred Income Tax 1018 996 1442 1795 2417
Minority Interest 54 49 71 67 66
Other Liabilities, Total 7343 7265 8244 8323 8660
Total Equity 41246 38693 46834 45991 44458
Common Stock 1788 1788 1788 1788 1788
Additional Paid-In Capital 44358 44219 44467 44379 44243
Retained Earnings (Accumulated Deficit) 57082 54198 62039 61081 59928
Treasury Stock - Common -57066 -56612 -56577 -56489 -56758
Unrealized Gain (Loss) 0
Other Equity, Total -4916 -4900 -4883 -4768 -4743
Total Liabilities & Shareholders’ Equity 106727 104469 107796 109160 107081
Total Common Shares Outstanding 2535.29 2539.43 2537.45 2537.83 2533.41
Short Term Investments 168 718 680 498 103
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 14526 12358 4523 9777 6193
Cash From Operating Activities 19095 14109 10253 13440 10922
Cash From Operating Activities 1824 1578 1669 3652 4519
Deferred Taxes -1568 187 -566 -556 -509
Non-Cash Items 5010 2189 7411 2634 2272
Cash Taxes Paid 3200 2400 2700 4500 1500
Cash Interest Paid 937 779 822 841 777
Changes in Working Capital -2782 -3839 -4601 -2067 -1553
Cash From Investing Activities -4960 -16555 -9443 -2629 4314
Capital Expenditures -4388 -4448 -4429 -3473 -2615
Other Investing Cash Flow Items, Total -572 -12107 -5014 844 6929
Cash From Financing Activities -9119 2593 -2832 -8861 -13160
Financing Cash Flow Items -240 8210 -436 5 -325
Total Cash Dividends Paid -7012 -6610 -6215 -5695 -5172
Issuance (Retirement) of Stock, Net 384 -638 -1192 -4419 -8500
Issuance (Retirement) of Debt, Net -2251 1631 5011 1248 837
Foreign Exchange Effects -410 -133 253 17 -205
Net Change in Cash 4606 14 -1769 1967 1871
Amortization 2085 1636 1817
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 2825 14526 11508 8256 4307
Cash From Operating Activities 1339 19095 14665 9063 4761
Cash From Operating Activities 448 1824 1394 895 421
Amortization 543 2085 1623 1163 699
Deferred Taxes -277 -1568 -1261 -600 -338
Non-Cash Items 690 5010 3836 2047 971
Cash Interest Paid 208 937 660 449 211
Changes in Working Capital -2890 -2782 -2435 -2698 -1299
Cash From Investing Activities -2359 -4960 -3212 -2250 -1173
Capital Expenditures -1007 -4388 -3239 -2113 -984
Other Investing Cash Flow Items, Total -1352 -572 27 -137 -189
Cash From Financing Activities -2054 -9119 -7565 -4863 -3086
Financing Cash Flow Items -81 -240 -172 -207 -103
Total Cash Dividends Paid -1853 -7012 -5262 -3515 -1745
Issuance (Retirement) of Stock, Net -119 384 119 109 12
Issuance (Retirement) of Debt, Net -1 -2251 -2250 -1250 -1250
Foreign Exchange Effects 87 -410 -776 -364 -55
Net Change in Cash -2987 4606 3112 1586 447
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 9.5576 242526408 -207362 2023-06-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.0885 129122317 -1852308 2023-06-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.6724 118562086 2174829 2023-06-30 LOW
Wellington Management Company, LLP Investment Advisor/Hedge Fund 3.0441 77245752 8681935 2023-06-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 2.0778 52723457 1504701 2023-06-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.4715 37339161 3092985 2023-06-30 LOW
Charles Schwab Investment Management, Inc. Investment Advisor 1.21 30705009 31668 2023-06-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 1.0237 25976060 -442039 2023-06-30 LOW
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 0.9719 24662395 1272794 2022-12-31 LOW
BofA Global Research (US) Research Firm 0.8545 21683505 -2217481 2023-06-30 LOW
Legal & General Investment Management Ltd. Investment Advisor/Hedge Fund 0.8152 20685604 1097735 2023-06-30 LOW
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund 0.7708 19560316 636989 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 0.7683 19496413 -2353237 2023-06-30 LOW
Morgan Stanley Smith Barney LLC Investment Advisor 0.752 19083401 -408910 2023-06-30 LOW
BlackRock Asset Management Ireland Limited Investment Advisor 0.6744 17111876 -368647 2023-06-30 LOW
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.6693 16983291 -1246863 2023-06-30 LOW
Nuveen LLC Pension Fund 0.6408 16260983 268735 2023-06-30 LOW
Columbia Threadneedle Investments (US) Investment Advisor/Hedge Fund 0.6389 16212389 -327705 2023-06-30 LOW
Managed Account Advisors LLC Investment Advisor 0.6167 15648355 -452944 2023-06-30 LOW
State Farm Insurance Companies Insurance Company 0.5608 14231200 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Merck - USD Company profile

Merck & Co., Inc. (MRK) is a healthcare company dealing in pharmaceuticals and animal health. Founded in 1891, Merck is headquartered in Kenilworth, New Jersey. 

The company provides pharmaceutical products around the world, offering an array of human healthcare solutions designed for areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular and diabetes. 

Apart from prescription medicines, Merck is known for its vaccine products for preventive diseases. A predecessor company to the present-day Merck made the first smallpox vaccine for commercial use in the United States in 1898 and was the maker of HPV vaccine Gardasil and painkiller Vioxx.

This biopharmaceutical company engages in research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. In 2021, Merck invested $12.2bn in research and development, especially to counter and help win the fight against coronavirus. It’s molnupiravir was given emergency use authorisation by the United States Food and Drug Administration (FDA) to counter mild-to-moderate Covid-19 in adults. 

Merck puts equal emphasis on animal health through Merck Animal Health, a research-driven company that develops, manufactures and markets a broad range of veterinary medicines and services.

The company engages and partners with several experts for early-stage science, clinical-stage programs, to deliver therapies and more. GlaxoSmithKline PLC (GSK), Johnson & Johnson (JJ) and many others are actively engaged with Merck.

Being more than a century old, Merck made it through two world wars and was a big part of the economic and business history of American public markets. Post-First World War, authorities seized the subsidiary of a German chemical maker to prevent the Kaiser from profiteering from American needs. Merck was re-established as an American corporation after the Second World War ended. 

The company went public on the New York Stock Exchange in 1946 under the symbol ‘MRK’.

Industry: Pharmaceuticals (NEC)

2000 Galloping Hill Road
KENILWORTH
NEW JERSEY 07033
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Oil - Crude

79.15 Price
-0.420% 1D Chg, %
Long position overnight fee 0.0267%
Short position overnight fee -0.0486%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,101.92 Price
+0.880% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.67 Price
+5.030% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

66,321.30 Price
+5.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading